Blue Owl Capital Holdings’s Marker Therapeutics MRKR Stock Holding History

Blue Owl Capital Holdings’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$815K	Hold	554,250	–	–	0.12%	36
2026 Q1	$721K	Hold	554,250	–	–	0.19%	39
2025 Q4	$826K	Hold	554,250	–	–	0.25%	40
2025 Q3	$495K	Hold	554,250	–	–	0.15%	41
2025 Q2	$848K	Hold	554,250	–	–	0.27%	38
2025 Q1	$682K	Hold	554,250	–	–	0.22%	37
2024 Q4	$1.72M	Buy	+554,250	New	+$1.96M	0.4%	31

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Blue Owl Capital Holdings's MRKR Position: Q2 2026 in Review

Blue Owl Capital Holdings held its Marker Therapeutics (MRKR) position steady in Q2 2026 at 554,250 shares worth $815K. The position accounts for 0.12% of the portfolio, ranked #36.

Blue Owl Capital Holdings first reported a position in MRKR in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.72M in Q4 2024. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

Blue Owl Capital Holdings held 554,250 shares of Marker Therapeutics worth $815K as of Q2 2026.
Blue Owl Capital Holdings left its Marker Therapeutics share count unchanged in Q2 2026.
Marker Therapeutics made up 0.12% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #36 holding.
Blue Owl Capital Holdings first reported a position in Marker Therapeutics in Q4 2024 and has held it in 7 quarters since.
Blue Owl Capital Holdings's Marker Therapeutics position peaked at $1.72M in Q4 2024.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.